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Abstract
Preoperative diagnostics of ovarian neoplasms rely on ultrasound imaging and the serum
biomarkers CA125 and HE4. However, these markers may be elevated in non-neoplastic
conditions and may fail to identify most non-serous epithelial cancer subtypes. The objec-
tive of this study was to identify histotype-specific serum biomarkers for mucinous ovarian
cancer. The candidate genes with mucinous histotype specific expression profile were iden-
tified from publicly available gene-expression databases and further in silico data mining
was performed utilizing the MediSapiens database. Candidate biomarker validation was
done using qRT-PCR, western blotting and immunohistochemical staining of tumor tissue
microarrays. The expression level of the candidate gene in serum was compared to the
serum CA125 and HE4 levels in a patient cohort of prospectively collected advanced ovar-
ian cancer. Database searches identified REG4 as a potential biomarker with specificity for
the mucinous ovarian cancer subtype. The specific expression within epithelial ovarian
tumors was further confirmed by mRNA analysis. Immunohistochemical staining of ovarian
tumor tissue arrays showed distinctive cytoplasmic expression pattern only in mucinous
carcinomas and suggested differential expression between benign and malignant mucinous
neoplasms. Finally, an ELISA based serum biomarker assay demonstrated increased
expression only in patients with mucinous ovarian cancer. This study identifies REG4 as a
potential serum biomarker for histotype-specific detection of mucinous ovarian cancer and
suggests serum REG4measurement as a non-invasive diagnostic tool for postoperative fol-
low-up of patients with mucinous ovarian cancer.
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Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer [1]. Although new
treatment modalities have prolonged survival during recent decades, the overall prognosis has
not improved [2,3]. The symptoms, such as abdominal pain, increased abdominal size, bloating
or nausea, are often non-specific until late in disease progression, leading to delayed diagnosis.
Most patients are diagnosed at an advanced stage and treated by surgery combined with plati-
num-taxane chemotherapy. EOC consists of six main histological subtypes (histotypes); low-
grade serous carcinoma (LGSC), high-grade serous carcinoma (HGSC), clear cell carcinoma
(CC), endometrioid carcinoma (EC), mucinous carcinoma (MC) and transitional cell carci-
noma (TC) with distinct genetic profiles, biological behavior and outcome.
The diagnosis of ovarian cancer relies on clinical features, ultrasound imaging and serum
biomarker Cancer antigen 125 (CA125). In addition, the novel serum biomarker Human epi-
didymis 4 (HE4) may bring additional information in differential diagnostics of women with
pelvic mass [4]. These biomarkers, however, are not completely reliable for diagnosing non-
serous histotypes. CA125 values have been shown to be lower for patients with MC compared
to patients with SC [5,6]. Since the diagnosis cannot be based on the current serum biomarkers,
in most cases the correct diagnosis is only revealed upon surgical intervention. Globally,
mucinous carcinomas account for ~11% of EOC [7]. Although the prognosis is usually favor-
able, in some cases carcinomas recur and progress aggressively [8,9]. Furthermore, mucinous
ovarian tumors have been shown to have lower response rate to platinum-based chemotherapy
when compared to HGSC [5,6]. An increasing number of studies indicates that different ovar-
ian cancer histotypes should be regarded as distinct diseases and therefore require different
treatment [10]. Non-invasive diagnostic methods, such as histotype differentiating serum tests,
could be valuable for optimization of treatment strategy before surgery.
This study aimed at identification of mucinous histotype specific serum biomarkers for
ovarian cancer. Based on in silico analyses, we studied the expression of Regenerating Islet-
Derived Protein IV (REG4) in a set of mucinous ovarian cancer tissues, patient sera and ascites
fluids. In addition, REG4 concentration was measured in a time series of serum samples to
determine the correlation to tumor burden. Furthermore, we examined CA125, HE4 and
REG4 in the same samples to compare their performance.
Materials and Methods
In silico data mining
The MediSapiens database (www.medisapiens.com) was applied to study the gene expression
levels across all normal and neoplastic human tissues [11]. The samples included in this data-
base have been analyzed on the Affymetrix platform and, because of the unique normalization
and data quality verifications, the gene expression profiles collected from different studies can
be combined to generate an overview of the expression profile in human tissues. The data from
normal ovary (n = 10) and ovarian cancer samples (n = 288) available in the MediSapiens data-
base were utilized in tissue specific expression analysis.
Clinical material
The studies involving clinical material have been performed in accordance with the ethical
standards laid down in the 1975 Declaration of Helsinki. The ovarian tissue microarray (TMA)
was constructed from surgical specimens collected from the tissue archive of Department of
Pathology, Turku University Central Hospital as previously described [12]. The use of the spec-
imens was approved by the The Ethics Committee of the Hospital District of Southwest
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Finland. Patient sera and part of the frozen tumor tissue specimens were collected from
patients treated at Turku University Hospital. The serum samples included both treatment-
naïve preoperative samples and longitudinal samples during treatment. The use of all clinical
material was approved by The Ethics Committee of the Hospital District of Southwest Finland
(ETMK, 53/180/2009 § 238) and The National Supervisory Authority for Welfare and Health
(Valvira, DNRO 6550/05.01.00.06/2010 and STH507A). Additional fresh frozen mucinous
ovarian tumor material was obtained from the Oslo University Hospital, Norway. Study
approval was given by the Regional Committee for Medical Research Ethics in Norway and
informed consent was signed by Norwegian patients.
Tissue microarray and immunohistochemistry
The TMA contained 185 samples from 100 patients with ovarian neoplasms; serous cystadeno-
mas (n = 16), serous borderline tumors (n = 27), serous carcinomas (n = 47), mucinous cysta-
denomas (n = 14), mucinous carcinomas (n = 36), endometroid carcinomas (n = 45). The
TMA was stained with mouse monoclonal REG4 antibody [13], as described [14]. REG4
immunostaining was independently evaluated by two investigators (TK and OC); in case of
disconcordance a consensus score was used for further evaluation.
Quantitative RT-PCR
Total RNA was extracted from frozen ovarian tumor samples (10 mg piece) and primary cells
using RNeasy Mini kit (Qiagen) according to the manufacturer’s protocol and processed to
cDNA (Applied Biosystems, Foster City, CA). TaqMan probes were acquired from the Univer-
sal Probe Library (Roche Diagnostics, Espoo, Finland) and primers were ordered from Oligo-
mer (Helsinki, Finland) for REG4 (forward: atgcggctgctcctattg; reverse: taaaaccatccaggagcaca)
and GAPDH (forward: tggctctaccttagaaccctga; reverse: ttttgctctttgccgtacct). Real-time quantita-
tive RT-PCR (qRT-PCR) was done with ABI Prism 7900 (Applied Biosystems). Quantitation
was carried out with RQ manager 1.2 software using the ΔΔCT method (Applied Biosystems).
Three or more replicate samples were used to study the mRNA expression of REG4 and
GAPDH. Average expression of the control samples was considered for the calculation of the
fold changes and GAPDH was used as an endogenous control. Three or more replicate samples
were studied for detection of mRNA expression. Statistical significance was determined with
student’s t-test, and p-values< 0.05 were considered statistically significant.
Western blotting
For protein lysates, approximately 20 mg pieces were cut from frozen tumors and lysed with soni-
cation in RIPA lysis buffer. Protein concentrations were measured using BioRad protein assay kit
according to manufacturer’s instructions (Bio-Rad Laboratories, CA). Samples were prepared mix-
ing appropriate amounts of protein lysate with 5 x Laemmli buffer and boiled for 5 min. Equal
amounts of protein (20 μg) were separated on 15% SDS-PAGE gel and transferred to nitrocellulose
membrane (pore width 0,2 μm). Equal loading was confirmed with Ponceau staining. Membranes
were blocked with 5%milk-TBST and probed with polyclonal REG4 antibody (1:1000, AF1379,
R&D Systems, Minneapolis, MN) and HRP-conjugated anti-goat secondary antibody (1:5000,
Dako, Glostrup, Denmark). Bound proteins were detected by enhanced chemiluminescence.
ELISA assay
The REG4 sandwich ELISA assays were performed using the Human REG4 ELISA Pair Set
(Sino Biological Inc., Beijing, China) according to the manufacturer’s instructions. The serum
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samples were diluted 1:1000 and ascites samples 1:500 in the sample dilution buffer. A pool of
serum samples from healthy males (n = 4) was used as a negative control. The absorbance at
450 nm was measured with Victor 1420 Multilabel Counter (Perkin Elmer, Waltham, MA). All
controls and samples were analyzed in two replicate wells in three individual runs.
Results
In silico data mining identifies REG4 as a biomarker candidate for
mucinous ovarian cancer
In order to identify putative serum biomarker candidates for ovarian cancer detection and his-
totype specification, we performed in silico analysis of gene expression data using the GTI algo-
rithm [15] and the MediSapiens database [11]. The analysis resulted in a list of 57 genes with
mucinous histotype specific mRNA expression profile (S1 Table). The aim was to concentrate
on genes highly expressed in malignant tissues with a secreted translational product. From the
resulting candidates, already known ovarian cancer biomarkers were ruled out (e.g. SPINK1/
TATI [16]), after which a more detailed analysis of the in silico expression data as well as rele-
vant literature was conducted. The final candidate selection identified the Regenerating Islet-
Derived Protein IV (REG4) as a potential serum biomarker for mucinous ovarian cancer histo-
type. REG4 is a member of the regenerating gene (REG) family, which belongs to the calcium-
dependent lectin superfamily. It consists of 17 members, from which REG1, REG2, REG3 and
REG4 have been associated with inflammation, diabetes and cancers [17].
REG4mRNA expression levels were studied in more detail using the MediSapiens database
which includes expression data of human tissue samples (see S1 and S2 Figs for complete
results). The overall REG4mRNA expression was significantly stronger in malignant tissues
(n = 15392) than in healthy tissues (n = 3082). The results are summarized in Fig 1, showing
malignant tissues (Fig 1A) with the highest REG4 mRNA expression levels (>500 in any sam-
ple) and their corresponding healthy tissues (Fig 1B). High expression of REG4mRNA was
found in malignant gastric, colorectal and pancreatic tissues as well as in healthy colorectal and
pancreatic tissues. The highest level of REG4mRNA expression was seen in mucinous ovarian
cancer, while the expression level remained very low in healthy ovarian tissue. More specific
analysis of REG4mRNA expression in healthy ovary (n = 10) and malignant (n = 288) ovarian
tissues of various histologies, confirmed the mucinous histotype specific expression profile
(p<0.001, Fig 1C). In other ovarian cancer histotypes, REG4mRNA expression remained at
the level of healthy tissues.
REG4 is highly expressed in tumor samples derived from mucinous
ovarian cancer
The in silico analysis indicated specific expression of REG4mRNA in mucinous histotype of
ovarian tumors. In order to validate these data, REG4mRNA and protein expression was stud-
ied in samples from mucinous (MUC) and high-grade serous (SER) ovarian tumors. The REG4
mRNA expression was studied with qRT-PCR using mRNA from serous tumors as negative
control. The results are summarized in Fig 2A. The REG4 mRNA showed high overall expres-
sion in mucinous carcinomas (MUC_C_4–10, Fig 2A) while no expression was detected in
high-grade serous tumors (SER_1–3). Interestingly, REG4 was not expressed in mucinous
cystadenoma (MUC_A_1) and showed significantly lower mRNA expression levels also in
mucinous borderline tumors (MUC_B_2–3). REG4 protein expression in the same set of
tumor samples was assessed with western blotting. The results indicated high REG4 protein
levels in REG4mRNA positive tumors (Fig 2B). Overall, REG4 protein expression was either
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Fig 1. In silico data mining identifies REG4 as mucinous ovarian cancer specific serum biomarker candidate. (A) Malignant tissues with high REG4
mRNA expression (exp. value > 500, n = 14). (B) REG4mRNA expression in corresponding healthy tissues (if available, n = 8). (C) Detailed analysis of
REG4mRNA expression in healthy and malignant ovarian tissues. The box refers to quartile distribution (25–75%) range, with the median shown as a
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very high or very low in these samples while mRNA analysis also identified samples with inter-
mediate or low expression. These results validate the findings of the in silico analysis and indi-
cate that REG4 expression is specific for mucinous ovarian cancer histotype.
REG4 is expressed by goblet-like cells of malignant mucinous ovarian
tumors
REG4 expression pattern was studied in TMAs containing clinical samples from ovarian
tumors with different histotypes. The results are summarized in Table 1 and in Fig 3.
vertical line (green in healthy samples, red in malignant). Data observations which lie more than 1.5*inter-quartile range higher than the third quartile, are
considered as outliers and indicated separately.
doi:10.1371/journal.pone.0151590.g001
Fig 2. REG4 is highly expressed in tumor samples derived frommucinous ovarian cancer. (A)
Quantitative RT-PCR analysis of REG4mRNA expression in serous carcinomas (SER_C), mucinous
cystadenomas (MUC_A), mucinous borderline tumors (MUC_B) and mucinous carcinomas (MUC_C). (B)
Western blot analysis of REG4 protein expression in the same set of samples. The total protein content of
each sample was 20 μg and equal loading was confirmed with ponceau staining.
doi:10.1371/journal.pone.0151590.g002
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Concurring with the previous analyses, no staining was detected in serous (n = 90) or endome-
trioid neoplasms (n = 45), while positive REG4 staining was found in 83% (30/36) of mucinous
carcinomas. This indicates that REG4 expression is specific for mucinous histotype. In all
REG4 positive samples the staining was very strong. The mucinous tissue samples were con-
firmed to be of primary ovarian tumor origin by examining the longitudinal electronic health
record information of each patient with special reference to previous diagnoses, diagnostic
examinations and laparotomy status, as well as with CK7/CK20 staining. The TMA also con-
tained samples of benign mucinous cystadenomas (n = 14). Importantly, no REG4 expression
was detected in these samples. Correlation of staining results with patient data showed no asso-
ciation of REG4 expression to other than mucinous histotype. Strong REG4 staining was
detected equally in low and high grade mucinous carcinomas. More detailed examination of
the REG4 staining pattern revealed the strongest staining inside and between the mucinous
inclusions of goblet-like tumor cells. Furthermore, REG4 was located exclusively on the apical
surface of the tumor cells, while the stroma was negative.
Secreted REG4 can be detected from serum and ascites of mucinous
cancer patients
To analyze the potential of REG4 as a serum biomarker for mucinous ovarian cancer, we used
a REG4 specific sandwich ELISA assay. The samples included sera and ascites fluid from
patients with serous or mucinous ovarian tumors. Detailed sample description and results are
presented in S2 Table. The serum samples were taken before (pre-operative) and after (post-
operative) surgery at several time points during follow-up. Ascites fluid was collected during
surgery. To assess the specificity of REG4 for mucinous ovarian cancer histotype, we analyzed
CA125, HE4 and REG4 concentrations from preoperative serum samples of ovarian cancer
patients with high-grade serous (n = 4) or mucinous (n = 3) cancers. All preoperative sera were
from patients with disseminated (stage III-IV) disease. The results are shown in Fig 4A. In
order to be able to directly compare the ELISA-assays with different units of measure, the
results are presented as fold-change (FC) of the respective malignancy indicating cut-off value
(35 kU/l for CA125 and 150 pM for HE4). The chosen cut-off values are based on current rec-
ommendations. Numerical values are presented in S2 Table. For REG4 the cut-off value was
set to 2 μg/l based on the highest REG4 concentration obtained from healthy male and a larger
Table 1. Immunohistochemical staining of REG4 in ovarian epithelial tumor tissues.
REG4 staining
Tumor type No. of samples pos neg Percentage of positive samples (%)
Serous carcinoma 47 0 47 0
Serous borderline 27 0 27 0
Serous cystadenoma 16 0 16 0
Endometrioid cystadenocarcinoma 45 0 45 0
Mucinous carcinoma 36 30 6 83
Grade 1 18 16 2 80
Grade 2 8 4 4 50
Grade 3 2* 2 0 100
Grade n/a 8 8 0 100
Mucinous cystadenoma 14 0 14 0
* Only one analyzed tumor
doi:10.1371/journal.pone.0151590.t001
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Fig 3. REG4 is expressed by goblet-like cells of malignant mucinous ovarian tumors. Immunohistochemical staining of REG4 in a TMA of malignant
ovarian tissues. Examples of serous carcinoma (A-B), endometrioid carcinoma (C-D) and mucinous carcinoma (E-F) are presented.
doi:10.1371/journal.pone.0151590.g003
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set of non-mucinous serum controls (S3 Table). A FC value> 1 is considered as a positive
result suggestive for malignancy, i.e. higher marker concentration than normally present in
healthy individuals. FC values 1 are considered as a negative results. The commonly used
serum biomarkers CA125 and HE4 showed elevated concentrations in the sera of high-grade
serous cancer patients (FC> 1) whereas the REG4 concentration remained below the cut-off
value (FC< 1) (Fig 4A). In the sera of mucinous cancer patients, the concentration of CA125
Fig 4. Secreted REG4 can be detected from serum and ascites of mucinous cancer patients. (A) ELISA analysis of REG4 protein concentration in sera
of patients diagnosed with serous (SER) or mucinous (MUC) ovarian carcinomas. (B) REG4 protein concentrations in a series of pre- (day -1) and post-
operative serum samples of one patient with diagnosed mucinous carcinoma.
doi:10.1371/journal.pone.0151590.g004
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and HE4 remained low. In these three samples the REG4 level was 10–70 fold over the cut-off
value. Although the amount of samples was low, these results indicate that REG4 is specific for
mucinous type tumors and can be detected at high concentrations in the sera of patients with
disseminated mucinous cancer. In addition to serum samples, REG4 concentration was mea-
sured from cell-free ascites fluids of two patients with mucinous tumors (M1 and M2, S2
Table). Both samples were positive (33 pg/ml and 187 pg/ml, respectively) for REG4 protein
indicating that mucinous tumor cells secrete REG4 also to the ascites fluid.
In order to determine the correlation of REG4, CA125 and HE4 concentrations to tumor
burden, serum samples were measured at multiple time points from a patient (M1) treated for
disseminated mucinous carcinoma (see S4 Table for detailed results). The results (FC of cut-off
value, Fig 4B) showed that the high concentration of REG4 (FC = 73.6) detected in the preopera-
tive sample (day 0) declined rapidly after surgery (day 13; FC = 4.9) and stayed on a low level
albeit higher than the cut-off value 2 μg/l. The concentration of CA125 indicated malignancy in
the three first time points (47 kU/l, 67 kU/l and 43 kU/l, respectively) after which it fell below the
cut-off value of 35 kU/l, while the levels of HE4 remained under the cut-off value of 150 pM in
all samples. This suggests that the REG4 concentration correlates to tumor burden better than
CA125 or HE4 in mucinous ovarian cancer. While CA125 measurement indicated malignancy
in the preoperative sample, HE4 measurement failed to detect the tumor in serum samples.
Discussion
Ovarian neoplasms differ in their genetic profiles, biological behavior and outcome, and should
be treated as distinct diseases already during surgical intervention. Thus, a specific preoperative
diagnosis is crucial for selection of optimal treatment strategy. Currently there are no methods
for preoperative discrimination of ovarian cancer subtypes and the specific diagnosis is reached
only by perioperative frozen section or postoperative histopathological analysis. Here we sug-
gest REG4 as a promising serum biomarker for separating mucinous cancers from other epi-
thelial ovarian cancer subtypes. According to our results, serum REG4 analysis may also have
potential for differentiation between benign and malignant mucinous neoplasms and for fol-
low-up of mucinous ovarian cancer patients.
The specific mucinous lineage expression of REG4 within ovarian neoplasms was demon-
strated by several ways. The first evidence was obtained from in silico analyses, which indicated
very specific mRNA expression profile of REG4 in mucinous cancers among various ovarian
tumor subtypes. REG4 expression was further validated with qRT-PCR and western blotting
from fresh frozen ovarian tumor tissue samples originating from serous and mucinous sub-
types. As expected based on the in silico data, REG4 was highly expressed only in malignant
mucinous ovarian tumors. Finally, immunohistochemical staining of a tumor tissue microarray
consisting of 185 tumor cores from benign and malignant serous, endometroid and mucinous
neoplasms confirmed restricted expression in the mucinous lineage. Interestingly, no REG4
expression was detected in mucinous cystadenomas suggesting that immunohistochemical
REG4 analysis could be used as an additional method for distinction between benign and
malignant mucinous ovarian tumors. All the mucinous samples were confirmed to be of pri-
mary ovarian tumor origin. Our sample set did not contain specimens of the more rare types of
mucinous ovarian carcinoma; such as endocervical/ seromucinous or foveolar types. Therefore,
in order to determine the true potential of REG4 as an immunohistochemical marker, addi-
tional analyses with wider range of different types of samples are needed.
The serum biomarkers CA125 and HE4 are used for ovarian cancer diagnostics and follow-
up. These markers mainly detect serous cancers [4,18,19], but are unreliable for diagnosis of
non-serous histotypes, especially the mucinous subtype [20,21]. Here, we compared serum
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samples from patients with high-grade serous or mucinous ovarian cancer. Our results corrob-
orate with earlier studies since in our sample set both CA125 and HE4 were significantly ele-
vated in preoperative serum samples of serous carcinoma patients, but remained low in the
mucinous carcinomas. In contrast, in all three mucinous cancer patients’ sera, REG4 level was
elevated more than ten-fold over the highest value of the control sera. The serum REG4 level
was not elevated in any of the serous cancer patients’ serum samples. Thus, a combination of
REG4 with CA125 and HE4 could provide a more comprehensive marker panel for preopera-
tive diagnosis of potentially neoplastic ovarian masses, and enable distinction of mucinous
ovarian cancer from other ovarian cancer histotypes. However, as some malignant tumors did
not show positive REG4 staining, we cannot exclude the possibility that a fraction of mucinous
cancers could remain undetectable in serum REG4 analysis. Since our serum sample collection
was limited, further analyses are needed to fully determine the role of REG4 serum measure-
ment as a pre-operative method for mucinous ovarian cancer diagnosis.
REG4 has been previously indicated as a serum biomarker in gastric, colorectal and prostate
cancer [22–24]. Thus, REG4 serum analysis alone may not be able to distinguish between pri-
mary mucinous ovarian cancer and ovarian metastases originating from the gastrointestinal
tract. On the other hand, addition of REG4 analysis from serum on the side of CA125 and/or
HE4 could provide a possibility for postoperative follow-up of mucinous ovarian cancer
patients with a confirmed diagnosis. Indication for this came from a longitudinal series of
serum samples from a patient with mucinous cancer. In this patient, the high preoperative
serum REG4 concentration was reduced rapidly postoperatively and remained low during the
uneventful follow-up period. To obtain definite proof of the utility of serum REG4 in disease
control, however, more patients with longitudinal serum samples should be tested.
The function of REG4 in ovarian cancer is poorly understood and has not been widely
investigated. A recent study suggests that REG4 modulates proliferation, apoptosis, migration
and invasion of ovarian cancer cells, and has an important role in early ovarian carcinogenesis
[25]. This study also reports immunohistochemical staining of REG4 from different ovarian
cancer subtypes. Serum REG4 values were not quantified in any ovarian cancer subtypes. In
contrast to our results, positive REG4 staining (from weak to strong) was also found in serous
samples. In our material REG4 protein expression was either very high or very low, and no
intermediate staining was observed. However, the qRT-PCR analysis of REG4 mRNA expres-
sion from fresh frozen mucinous ovarian tumors identified samples with intermediate or low
expression, yet no expression was detected in samples from serous ovarian tumors. This might
be due to differences in antibody specificity and the scaling of staining strength.
In conclusion, we identified REG4 as a potential biomarker for subtype specific diagnosis of
mucinous ovarian cancer as well as for disease follow-up. According to our results REG4 pro-
tein is secreted into circulation by mucinous ovarian tumor cells and can be detected with an
ELISA-based test. We measured three biomarkers from patient sera; CA125, HE4 and REG4
and found high concentrations of REG4 in preoperative samples of mucinous ovarian cancer
patients, whereas CA125 and HE4 failed to convincingly detect malignancy in these samples.
Our study suggests that combining REG4 with CA125 and HE4 could provide added value for
preoperative diagnostics of ovarian masses of potential neoplastic origin, and enable distinction
of mucinous ovarian cancer from other ovarian cancer subtypes with non-invasive methods.
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